ANG Lifesciences India (BOM:540694) Moat Score: 0/10 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540694 ANG Lifesciences India Ltd BOM:540694
62 GF Score
Price ₹36.43
GF Value ₹30.51
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is ANG Lifesciences India Moat Score?

ANG Lifesciences India has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

ANG Lifesciences India has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ANG Lifesciences India might have No Moat - No discernible moat.

ANG Lifesciences India  (BOM:540694) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ANG Lifesciences India Moat Score Related Terms

BOM:540694
62GF Score
ANG Lifesciences India Ltd BOM:540694
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?

Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued. The current stock price of ₹36.43 is trading 19.4% above its estimated GF Value™ of ₹30.51. GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.

Key valuation signals for BOM:540694:

  • Moat Score: 0
  • GF Value™: ₹30.51 vs. price of ₹36.43 (19.4% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANG Lifesciences India Business Description

Address Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
62GF Score

Get the complete analysis for BOM:540694

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹36.43
Price
₹30.51
GF Value